Egis Pharmaceuticals's operating cash flow stood at HUF 26,342 mil in 2012, down 0.697% when compared to the previous year. Historically, between 2003 - 2012, the firm’s operating cash flow reached a high of HUF 26,527 mil in 2011 and a low of HUF 6,037 mil in 2003.
Egis Pharmaceuticals's total investments stood at HUF -14,896 mil and accounted for 11.5% of sales in 2012. This is compared to an average of 12.1% as seen over the last five years.
Cash from financing amounted to HUF -1,074 mil, so the company generated HUF 10,372 mil net cash in 2012.
At the end of 2012, the company had a net debt of HUF -43,021 mil, or -1.41x of EBITDA and -0.240 of equity. Net working capital amounted to HUF 50,982 mil, or 38.4% of sales. Cash conversion cycle is negative and reached 207 days days in 2012. This means Egis Pharmaceuticals generates revenue from customers before it has to pay its suppliers for inventory, among other things.
You can see all the company’s data at Egis Pharmaceuticals profile, or you can download a report on the company in the report section.
Helgi Library 
